Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease

Onkologie

Volumn 32, Issue 8-9, 2009, Pages 482-486

  Henrich, Dirk M ^a,b   Hoffmann, Martin ^b   Uppenkamp, Michael ^b   Bergner, Raoul ^b  

^a Dialysezentrum Saarlouis ^*  (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Bisphosphonates; End stage renal disease; Ibandronate; Multiple myeloma; Myeloma bone disease

Indexed keywords

IBANDRONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE DISEASE; BONE PAIN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MULTIPLE MYELOMA; MYALGIA; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OPEN STUDY; SURVIVAL RATE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 70149113816     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226141     Document Type: Article

References (39)

1. Coleman RE: Metastatie bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
2. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.
3. Coleman RE: Clinical features of metastatie bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s.
4. Abe M, Hiura K, Wilde J, Shioyasono A, Mori-yama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-2491.
5. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J: Myeloma interacts with the bone marrow microenvironment to induce osteo-clastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
6. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA: Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-198.
7. Body JJ, Mancini I: Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002;10:399-407.
8. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736.
9. Russell RG: Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(suppl 2):S150-S162.
10. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
11. Russell RG: Bisphosphonates: from bench to bedside Ann N Y Acad Sci 2006;1068:367-401.
12. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
13. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
14. Berenson JR, Lichtenstein A, Porter L, Dimopou-los MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events; Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
15. Goldschmidt H, Lannert H, Bommer J, Ho AD: Multiple myeloma and renal failure. Nephrol Dial Transplant 2000;15:301-304.
16. Iggo N, Palmer AB, Severn A, Trafford JA, Mufti GJ, Taube D, Parsons V: Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989;73:903-910.
17. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-1445.
18. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-290.
19. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Jr, Ravera C, Schran H, Seaman J, Wald-meier F: The pharmacokinetics and pharmacody-namics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154-162.
20. Beigel AE, Rienhoff E, Olbricht CJ: Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 1995;10:2266-2268.
21. Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A: Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant 1999;14:699-705.
22. Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L: Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 2006;11:197-200.
23. Bergner R, Dill K, Boerner D, Uppenkamp M: Elimination of intravenously administered iband-ronate in patients on hemodialysis: a monocenter open study. Nephrol Dial Transplant 2002;17:1281-1285.
24. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-2359.
25. Heidenreich A, Ohlmann C, Bergner R: Renal safety of loading-dose ibandronate in urologic patients with compensated renal insufficiancy. Cancer Treat Rev 2005;31(suppl l):S50.
26. Kurth AA, Pilz M, Stumpf U, Muller A, Eberhardt C: Reduced bone pain by intensive bisphosphonatetherapy of new diagnosed bone metastases. Bone 2006;38:S77.
27. Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M: Renal safety and pharmakokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007;47: 942-950.
28. Bondronat package insert: Ibandronic acid prescribing information. Hertfordshire, Roche Ltd., 1996.
29. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI): Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, www.kidneyorg/professionals/ kdoqi/guidelines-ckd/to-chtm, 2000.
30. Barrett J, Worth E, Bauss F, Epstein S: Ibandronate: a clinical pharmacological and pharmacoki-netic update. J Clin Pharmacol 2004;44:951-965.
31. Adami S, Zamberlan N: Adverse effects of bisphosphonates -a comparative review. Drug Saf 1996; 14:158-170.
32. Thiebaud D, Sauty A, Burckhardt P, Leuenberg-er P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61:386-392.
33. Diel IJ, Bergner R, Grotz KA: Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-482.
34. Bauss F, Endele R, Bendelder E: Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcif Tissue Int 2002;70:289-290.
35. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P: Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-330.
36. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K: Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492.
37. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI: Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998;32:129-138.
38. Coleman RE: Bisphosphonates for the prevention of bone metastases. Semin Oncol 2002;29:43-49.
39. Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A: Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 2007;31:341-352.